^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAR19T2 T cells

    i
    Other names: CAR19T2 T cells, third-generation autologous T cells
    Associations

    News

    Trials
    Company:
    Zhaotai InVivo Biomedicine
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    CAR19T2: CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Zhujiang Hospital | N=70 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    CD19 positive
    |
    cyclophosphamide • CAR19T2 T cells
    2years
    CAR19T2: CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Zhujiang Hospital
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • CAR19T2 T cells